Month: October 2024

At the 2024 European Society for Medical Oncology (ESMO) Congress, Dr. Myriam Chalabi from Amsterdam, Netherlands, unveiled the latest results from the NICHE-2 study, showing a groundbreaking three-year disease-free survival (DFS) rate of 100% in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer undergoing neoadjuvant immunotherapy. This large-scale study provides critical evidence supporting neoadjuvant immunotherapy, overcoming the limitations of the NICHE-1 study, which had a smaller sample size. In this article, we summarize the key findings of NICHE-2 and discuss the latest results from NICHE-3, presenting the latest advancements in this field.

The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting took place from September 13 to 17 in Barcelona, Spain. The team led by Dr. Yao Zhu from Fudan University Shanghai Cancer Center presented their research on the neoadjuvant treatment of localized high-risk prostate cancer, featuring a combination of ARSi and PARPi, which was selected for poster presentation (1625P). In an exclusive interview with Urology Frontier, Dr. Yao Zhu shared insights into how their research is contributing to the global understanding and treatment of prostate cancer, showcasing China’s expertise in this field.

Dr. Jiafu Ji, Dr. Ziyu Li, and Dr.  Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal antibody treatment, the high incidence of adverse effects with PD-1 and CTLA-4 combination therapy, and the ineffectiveness of PD-1 combined with chemotherapy in patients with low or negative CPS scores. To tackle these challenges, the researchers innovatively employed a domestically developed PD-1/CTLA-4 dual-target antibody in the COMPASSION-04 study, marking the first clinical trial globally to evaluate this combination as a first-line treatment for advanced gastric cancer.

The release of studies like HIMALAYA has marked the beginning of the dual immunotherapy era in advanced liver cancer treatment. As the majority of Chinese liver cancer patients are diagnosed at an advanced stage, finding the optimal systemic therapy, including durvalumab, in combination with local therapies to further improve patient outcomes has become a research focus. At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, held from September 13 to 17 in Barcelona, Spain, Dr. Rongping Guo's team from Sun Yat-sen University Cancer Center presented the results of their HILL study (982P) in a poster session. The study demonstrated that the combination of durvalumab, lenvatinib, and hepatic arterial infusion chemotherapy (HAIC) achieved a 2-year overall survival (OS) rate of 94%, with manageable side effects, contributing valuable insights from China for the treatment of advanced liver cancer. Oncology Frontier invited Dr. Rongping Guo for an in-depth interview to discuss the study.

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13-17 in Barcelona, Spain. As one of the largest and most prestigious global clinical oncology conferences, it showcased groundbreaking research from experts around the world, advancing the field of oncology. In the hematologic malignancy space, this year's ESMO also featured many key advancements, including research from China. One such study, led by Dr. Hongyan Tong from The First Affiliated Hospital of Zhejiang University Medical College, was selected for an oral presentation. The study explored the efficacy of Timdarpacept (IMM01) combined with azacitidine (AZA) as a first-line treatment for chronic myelomonocytic leukemia (CMML) (801 MO). Hematology Frontier had the opportunity to interview Dr. Maria Ma, one of the team members, who provided an in-depth explanation of the study.